Prevention and treatment of recurrent Hepatitis B after liver transplantation: The current role of nucleoside and nucleotide analogues

Annals of Clinical Microbiology and Antimicrobials

Volumn 5, Issue , 2006, Pages

  Schreibman, Ian R ^a   Schiff, Eugene R ^a  

^a UNIVERSITY OF MIAMI MILLER SCHOOL OF MEDICINE   (United States)

Author keywords

[No Author keywords available]

Indexed keywords

ADEFOVIR DIPIVOXIL; AMINOTRANSFERASE; ANTIVIRUS AGENT; CALCINEURIN INHIBITOR; DNA; EMTRICITABINE PLUS TENOFOVIR DISOPROXIL; ENTECAVIR; HEPATITIS B ANTIBODY; INTERFERON; LAMIVUDINE; NUCLEOSIDE ANALOG; NUCLEOTIDE DERIVATIVE; RNA DIRECTED DNA POLYMERASE INHIBITOR; TENOFOVIR DISOPROXIL;

ANTIVIRAL ACTIVITY; CLINICAL TRIAL; DEATH; DNA SYNTHESIS INHIBITION; DNA VIRUS; DRUG EFFICACY; FLUSHING; GRAFT SURVIVAL; HEADACHE; HEALTH CARE COST; HEALTH CARE UTILIZATION; HEPATITIS B; HEPATITIS B VIRUS; HUMAN; INFECTION RISK; KIDNEY DYSFUNCTION; LIVER CELL CARCINOMA; LIVER CIRRHOSIS; LIVER DISEASE; LIVER FAILURE; LIVER GRAFT REJECTION; LIVER TRANSPLANTATION; NEPHROTOXICITY; NONHUMAN; RECURRENCE RISK; RECURRENT DISEASE; RECURRENT INFECTION; REVIEW; SIDE EFFECT; THORAX PAIN; VIRUS INHIBITION; VIRUS LOAD; VIRUS MUTATION; VIRUS STRAIN;

ADENINE; ANTIVIRAL AGENTS; DRUG THERAPY, COMBINATION; GUANINE; HEPATITIS B; HUMANS; IMMUNOGLOBULINS; LAMIVUDINE; LIVER TRANSPLANTATION; NUCLEOSIDES; NUCLEOTIDES; ORGANOPHOSPHONATES; RECURRENCE;

EID: 33646584217     PISSN: 14760711     EISSN: 14760711     Source Type: Journal    
DOI: 10.1186/1476-0711-5-8     Document Type: Review

References (91)

1. Lee WM: Hepatitis B virus infection. N Engl J Med 1997, 337:1733-1745.
2. Poland GA, Jacobson RM: Prevention of Hepatitis B with the Hepatitis B vaccine. N Engl J Med 2004, 351:2832-2838.
3. Villeneuve JP, Condrey LD, Willems B, et al.: Lamivudine treatment for decompensated cirrhosis resulting from chronic Hepatitis B. Hepatalogy 2000, 31:207-210.
4. Yao FY, Bass NM: Lamivudine treatment in patients with severely decompensated cirrhosis due to replicating hepatitis B infection. J Hepatol 2000, 33:301-307.
5. Kapoor D, Guptan RC, Wakil SM, et al.: Beneficial effects of lamivudine in Hepatitis B virus-related decompensated cirrhosis. J Hepatol 2000, 33:308-312.
6. Perillo RP, Wright T, Rakela J, et al.: A multicenter United States-Canadian trial to assess lamivudine monotherapy before and after transplantation for chronic Hepatitis B. Hepatalogy 2001, 33:424-432.
7. Yao FY, Terrault NA, Freise C, et al.: Lamivudine treatment is beneficial in patients with severely decompensated cirrhosis and actively replicating Hepatitis B infection awaiting liver transplantation: A comparative study using a matched untreated cohort. Hepatology 2001, 34:411-416.
8. Seaberg EC, Belle SH, Beringer KC, et al.: Liver transplantation in the United States from 1987-1998: Updated results from the Pitt-UNOS liver transplant registry. In Clinical Transplants Edited by: Cecka, JM, Terasaki, PI. UCLA Tissue Typing Laboratory: Los Angeles; 1998.
9. Todo S, Demetris AJ, Van Thiel D, et at.: Orthotopic liver transplantation for patients with Hepatitis B virus-related liver disease. Hepatalogy 1991, 13:619-626.
10. O'Grady JG, Smith HM, Davies SE, et al.: Hepatitis B virus reinfection after orthotopic liver transplantation. Serological and clinical implications. J Hepatol 1992, 14:104-111.
11. Davies SE, Portmann BC, O'Grady JG, et al.: Hepatic histological findings after transplantation for chronic Hepatitis B virus infection, including a unique pattern of fibrosing cholestatic hepatitis. Hepatology 1991, 13:150-157.
12. Papatheodoridis GV, Sevastianos V, Burroughs AK: Prevention of and treatment for Hepatitis B virus infection after liver transplantation in the nucleoside analogues era. Am J Transplant 2003, 3:250-258.
13. Rosenau J, Bahr M, Tillmann HL, et al.: Lamivudine and low-dose Hepatitis B immune globulin for prophylaxis of Hepatitis B reinfection after liver transplantation: Possible role of mutation in the YMDD motif prior to transplantation as a risk factor for reinfection. J Hepatalogy 2001, 34:895-902.
14. Walsh KM, Woodall T, Lamy P, et al.: Successful treatment with adefovir dipivoxil in a patient with fibrosing cholestatic hepatitis and lamivudine resistant Hepatitis B virus. Gut 2001, 49:436-440.
15. Mutimer D, Feraz-Neto BH, Harrison R. et al.: Acute liver graft failure due to emergence of lamivudine resistant Hepatitis B virus: Rapid resolution during treatment with adefovir. Gut 2001, 49:860-863.
16. Wai C-T, Prabhakaran K, Wee A, et al.: Adefovir dipivoxil as the rescue therapy for lamivudine-resistant Hepatitis B post liver transplant. Transplantation Proceedings 2004, 36:2313-2314.
17. Akay S, Karasu Z, Akyildiz M, et al.: Adefovir treatment in post-transplant Hepatitis B virus infection resistant to lamivudine plus Hepatitis B virus immunoglobulin. Transplantation Proceedings 2004, 36:2768-2770.
18. Seehofer D, Rayes N, Steinmüller T, et al.: Occurrence and clinical outcome of lamivudine-resistant Hepatitis B infection after liver transplantation. Liver Transplantation 2001, 7:976-982.
19. Neff GW, O'Brien CB, Nerry J, et al.: Outcomes in liver transplant recipients with Hepatitis B virus: Resistance and recurrence patterns from a large transplant center over the last decade. Liver Transplantation 2004, 10:1372-1378.
20. Villeneuve JP, Durantel D, Durantel S, et al.: Selection of a Hepatitis B virus strain resistant to adefovir in a liver transplantation patient. J Hepatol 2003, 39:1085-1089.
21. Neff GW, Nery J, Lau DT, et al.: Tenofovir therapy for lamivudine resistance following liver transplantation. Ann Pharmacotherapy 2004, 38:1999-2004.
22. Toniutto P, Fumo E, Caldato M, et al.: Favourable outcome of adefovir-dipivoxil treatment in acute de novo Hepatitis B after liver transplantation. Transplantation 2004, 77:472-473.
23. Samuel D, Muller R, Alexander G, et al.: Liver transplantation in European patients with the Hepatitis B surface antigen. N Engl J Med 1993, 329:1842-1847.
24. Terrault NA, Zhou S, Combs C, et al.: Prophylaxis in liver transplant recipients using a fixed dosing schedule of Hepatitis B immunoglobulin. Hepatology 1996, 24:1327-1333.
25. Muller R, Gubernatis G, Farle M, et al.: Liver transplantation in HBs antigen (HBsAg), carriers: Prevention of Hepatitis B virus (HBV) recurrence by passive immunization. J Hepatol 1991, 13:90-96.
26. Samuel D, Bismuth A, Mathieu D, et al.: Passive immunoprophylaxis after liver transplantation in HBsAg-positive patients. Lancet 1991, 337:813-815.
27. Rinoldi P, Belli L, Rondinara G, et al.: Recurrent HBV/HDV infections under different immunoprophylaxis protocols. Transplant Proc 1993, 25:2675-2676.
28. Steinmuller T, Seehoffer D, Rayes N, et al.: Increasing applicability of liver transplantation for patients with Hepatitis B-related liver disease. Hepatology 2002, 35:1528-1535.
29. Mohanty SR, Cotler SJ: Management of Hepatitis B in liver transplant patients. J Clin Gastroenterol 2005, 39:58-63.
30. McGory RW, Ishitani MB, Oliveira WM, et al.: Improved outcome of orthotopic liver transplantation for chronic Hepatitis B cirrhosis with aggressive passive immunization. Transplantation 1996, 61:1358-1364.
31. Konig V, Hopf U, Neuhaus P, et al.: Long-term follow-up of Hepatitis B virus-infected recipients after orthotopic liver transplantation. Transplantation 1994, 58:553-559.
32. Samuel D, Bismuth A, Serres C, et al.: HBV infection after liver transplantation in HBsAg positive patients: Experience with long-term immunoprophylaxis. Transplant Proc 1991, 33:1492-1494.
33. Sawyer RG, McGory RW, Gaffey MJ, et al.: Improved clinical outcomes with liver transplantation for Hepatitis B- induced chronic liver failure using passive immunization. Ann Surg 1998, 227:841-50.
34. Cooreman MP, Leroux-Roels G, Paulij WP, et al.: Vaccine and Hepatitis B immune globulin-induced escape mutations of Hepatitis B virus surface antigen. J Biomed Sci 2001, 8:237-247.
35. Fung J, Ostberg L, Shapiro R, et al.: Human monoclonal antibody against Hepatitis B surface antigen in preventing recurrent Hepatitis B following liver transplantation. In Viral Hepatitis and Liver Disease Edited by: Hollinger FB, Lemon, SM, and Margolis, HS. Baltimore: Williams and Wilkins; 1991.
36. McMahon G, Ehrlich PH, Moustafa ZA, et al.: Genetic alterations in the gene encoding the major HBsAg: DNA and immunological analysis of recurrent HBSAg derived from monoclonal antibody-treated liver transplant patients. Hepatology 1992, 15:755-766.
37. Galun E, Eren R, Safadi R, et al.: Clinical evaluation (Phase I) of a combination of two human monoclonal antibodies to HBV: Safety and antiviral properties. Hepatology 2002, 35:673-679.
38. Lai CL, Chien RN, Leung NW, et al.: A one-year trial of lamivudine for chronic Hepatitis B: Asia hepatitis lamivudine study group. N Engl J Med 1998, 339:61-68.
39. Dienstag JL, Perrilo RP, Schiff ER, et al.: A preliminary trial of lamivudine for chronic Hepatitis B infection. N Engl J Med 1995, 333:1657-1661.
40. Marzano A, Salizzoni M, Debernardi-Venon W, et al.: Prevention of Hepatitis B virus recurrence after liver transplantation in cirrhotic patients treated with lamivudine and passive immunoprophylaxis. J Hepatol 2001, 34:903-910.
41. Grellier L, Mutimer D, Ahmed M, et al.: Lamivudine prophylaxis against reinfection in liver transplantation for Hepatitis B cirrhosis. Lancet 1996, 348:1212-1215.
42. Markowitz JS, Martin P, Conrad AJ, et al.: Prophylaxis against Hepatitis B recurrence following liver transplantation using combination lamivudine and Hepatitis B immune globulin. Hepatology 1998, 28:585-589.
43. Lo CM, Cheung ST, Lai CL, et al.: Liver transplantation in Asian patients with chronic Hepatitis B using lamivudine prophylaxis. Ann Surg 2001, 233:276-281.
44. Seehofer D, Rayes N. Naumann U, et al.: Preoperative antiviral treatment and postoperative prophylaxis in HBV-DNA positive patients undergoing liver transplantation. Transplantation 2001, 72:1381-1385.
45. Fontana RJ, Keefe EB, Carey W, et al.: Effect of lamivudine treatment on survival of 309 North American patients awaiting liver transplantation for chronic Hepatitis B. Liver Transplant 2002 8:433-439.
46. Andreone P, Biselli M, Gramenzi A, et al.: Efficacy of lamivudine therapy for advanced liver disease in patients with precore mutant Hepatitis B virus infection awaiting liver transplantation. Transplantation 2002, 8:1119-1124.
47. Fontana RJ, Hann HW, Perrillo RP, et al.: Determinants of early mortality in patients with decompensated chronic Hepatitis B treated with antiviral therapy. Gastroenterology 2002, 123:719-727.
48. Dienstag JL, Schiff ER, Wright TL, et al.: Lamivudine as initial treatment for chronic Hepatitis B in the United State. N Engl J Med 1999, 341:1256-1263.
49. Schalm SW, Heathcote J, Cianciara J, et al.: Lamivudine and alfa interferon combination treatment of patients with chronic Hepatitis B infection: A randomized trial. Gut 2000, 46:562-568.
50. Liaw YF, Leung NW, Chang TT, et al.: Effects of extended lamivudine therapy in Asian patients with chronic Hepatitis B: Asia hepatitis lamivudine study group. Gastroenterology 2000, 119:172-180.
51. Leung NW, Lai CL, Chang TT, et al.: Extended lamivudine treatment in patients with chronic Hepititis B enhances Hepatitis B e antigen seroconversion rates: results after 3 years of therapy. Hepatology 2001, 33:1527-1532.
52. Stuyver LJ, Locarnini SA, Lok A, et al.: Nomenclature for antiviral-resistant human Hepatitis B mutations in the polymerase region. Hepatology 2001, 33:751-757.
53. Liaw Y-F: Results of lamivudine in Asian trials. Proceedings of EASL International Consensus Conference on Hepatitis B 2002.
54. Zoulim F: A preliminary benefit-risk assessment of lamivudine for the treatment of chronic Hepatitis B virus infection. Drug Safety 2002, 25:497-510.
55. Mutimer D, Dushieko G, Barrett C. et al.: Lamivudine without HBIg for prevention of graft reinfection by Hepatitis B: Long-term follow-up. Transplantation 2000, 70:809-815.
56. Vierling J: Management of HBV infection in liver transplant recipients. Int J Med Sci 2005, 2:41-49.
57. Malkan G, Cattral M, Humar A, et al.: Lamivudine for Hepatitis B in liver transplantation. Transplantation 2000, 69:1403-1407.
58. Roche B, Samuel D: Transplantation for viral Hepatitis A and B. In Transplantation of the Liver Edited by: Busutill, RW, and Klintmalm, GB. Philadelphia: Elsevier, 2005:115-129.
59. Roche B, Samuel D, Roque AM, et al.: Lamivudine therapy for HBV infection after liver transplantation. J Hepatol 1999, 30:78.
60. Angus PW, McCaughan GW, Gane EJ, et al.: Combination low-dose Hepatitis B immune globulin and lamivudine therapy provides effective prophylaxis against posttransplantation Hepatitis B. Liver Transpl 2000, 6:429-433.
61. Yao FY, Osario RW, Roberts JP, et al.: Intramuscular Hepatitis B immune globulin combined with lamivudine for prophylaxis against Hepatitis B recurrence after liver transplantation. Liver Transpl Surg 1999, 5:491-496.
62. Yoshida EM, Erb SR, Partovi N, et al.: Liver transplantation for chronic Hepatitis B infection with the use of combination lamivudine and low-dose Hepatitis B immune globulin. Liver Transpl Surg 1999, 5:520-525.
63. McCaughan GW, Spencer J, Koorey D, et al.: Lamivudine therapy in patients undergoing liver transplantation for Hepatitis B virus precore mutant-associated infection: High resistance rates in treatment of recurrence but universal prevention if used as prophylaxis with very low dose Hepatitis B immune globulin. Liver Transpl Surg 1999, 6:512-519.
64. Han SH, Ofman J, Holt C, et al.: An efficacy and cost-effectiveness analysis of combination Hepatitis B immune globulin and lamivudine to prevent recurrent Hepatitis B after orthotopic liver transplantation compared with Hepatitis B immune globulin monotherapy. Liver Transpl 2001, 6:741-748.
65. Seehofer D, Rayes N, Naumann U, et al.: Preoperative antiviral treatment and postoperative prophylaxis in HBV-DNA positive patients undergoing liver transplantation. Transplantation 2001, 72:1381-1385.
66. Gane EJ, McCaughan G, Crawford D, et al.: Combination lamivudine plus low dose intramuscular Hepatitis B immunoglobulin prevents recurrent Hepatitis B and may eradicate residual graft infection. Hepatology 2002, 36:221A.
67. Marcellin P, Chang T-T, Lim SG, et al.: Adefovir dipivoxil for the treatment of Hepatitis B e antigen positive Hepatitis B. N Eng J Med 2003, 348:808-816.
68. Hadziyannis SJ, Tassopoulos N, Heathcote EJ, et al.: Adefovir dipivoxil for the treatment of Hepatitis B e antigen negative Hepatitis B. N Eng J Med 2003, 348:800-807.
69. Benhamou Y, Bochet M, Thibault V, et al.: Safety and efficacy of adefovir dipivoxil in patients co-infected with HIV-I and lamivudine-resistant Hepatitis B virus: An open label pilot study. Lancet 2001, 358:718-723.
70. Deeks SG, Collier A, Larezra J, et al.: The safety and efficacy of Adefovir dipivoxil, a novel anti-human immunodeficiency virus (HIV) therapy in HIV-infected adults. A randomized, double-blind, placebo-controlled trial. J Infect Dis 1997, 176:1517-1523.
71. Schiff ER, Lai C-L, Hadziyannis S, et al.: Adefovir dipivoxil therapy for lamivudine-resistant Hepatitis B in pre- and post-liver transplantation patients. Hepatology 2003, 38:1419-1427.
72. Lo CM, Li CL, Lau GK, et al.: Liver transplantation for chronic Hepatitis B with lamivudine-resistant YMDD mutant using add-on adefovir dipivoxil plus lamivudine. Liver Transplantation 2005, 11:807-813.
73. Yang H, Westland CE, Delaney WET, et al.: Resistance surveillance in chronic Hepatitis B patients treated with adefovir dipivoxil for up to 60 weeks. Hepatology 2002, 36:464-473.
74. Xiong S, Yang H, Westland C, et al.: Resistance surveillance of HBeAg-chronic Hepatitis B patients treated for 2 years with adefovir dipivoxil. J Hepatol 2003, 38:A4543.
75. Locarninin S, Qi X, Arterburn S, et al.: Incidence and predictors of emergence of adefovir resistant HBV during four years of adefovir dipivoxil (ADV) therapy for patients with chronic Hepatitis B (CHB). J Hepatol 2005, 42(Suppl 2):A36.
76. Fung SK, Andreone P, Han SH, et al.: Adefovir-resistant Hepatitis B can be associated with viral rebound and hepatic decompensation. J Hepatol 2005, 43:937-943.
77. Fung SK, Chae HB, Fontana RJ, et al.: Virologic response and resistance to adefovir in patients with chronic Hepatitis B. J Hepatol 2006, 44:283-290.
78. Snow A, Thibault V, Qi X, et al.: Combination of adefovir (ADV) and lamivudine (LAM) prevented emergence of adefovir resistance mutations in chronic Hepatitis B patients with lamivudine-resistant HBV. Gastroenterology 2005, 128:M945.
79. Perillo R, Rakela J, Dienstag J, et al.: Multicenter study of lamivudine therapy for Hepatitis B after liver transplantation. Hepatology 1999, 29:1581-1586.
80. Rayes N, Seehofer D, Hopf U, et al.: Comparison of famciclovir and lamivudine in the long-term treatment of Hepatitis B infection after liver transplantation. Transplantation 2001, 71:96-101.
81. Fontana RJ, Hann HW, Wright T, et al.: A multicenter study of lamivudine treatment in 33 patients with Hepatitis B after liver transplantation. Liver Transpl 2001, 6:504-510.
82. Echanojauregui A, Planas J, Gonzalez E, et al.: Adefovir dipivoxil therapy in liver transplant recipients with lamivudine-resistant Hepatitis B virus. Transplantation Proceedings 2005, 37:1507-1508.
83. Beckebaum S, Malago M, Dirsch O, et al.: Efficacy of combined lamivudine and adefovir dipivoxil treatment for severe HBV graft reinfection after liver donor liver transplantation. Clin Transplant 2003, 17:554-559.
84. Honkoop P, de Man RA: Entecavir: A patent new antiviral drug for Hepatitis B. Expert Opin Investig Drugs 2003, 12:683-688.
85. de Man RA, Wolters LM, Nevens F, et al.: Safety and efficacy of oral entecavir given for 28 days in patients with chronic Hepatitis B infections. Hepatology 2001, 34:578-582.
86. Wolters LM, Hansen BE, Niesters HG, et al.: Viral dynamics during and after entecavir therapy in patients with chronic Hepatitis B. J Hepatol 2002, 37:137-144.
87. Shakil AO, Angus P, Gerken G, et al.: Entecavir reduces viral load in liver transplant patients who have failed prophylaxis or treatment for Hepatitis B. Hepatalogy 2001, 34:619A.
88. Kuo A, Dienstag JL, Chung RT, et al.: Tenofovir disoproxil fumarate for the treatment of lamivudine-resistant Hepatitis B. Clin Gastroenterol Hepatol 2004, 2:266-272.
89. Van Bommel F, Schernick A, Hopf U, et al.: Tenofovir disoproxil fumarate exhibits strong antiviral effect in a patient with lamivudine-resistant severe Hepatitis B reactivation. Gastroenterology 2003, 124:586-587.
90. Van Bommel F, Wunsche T, Schurmann D, et al.: Tenofovir treatment in patients with lamivudine-resistant Hepatitis B mutants strongly affects viral replication. Hepatology 2002 36:507-508.
91. Taltavull TC, Chahri N, Verdura B, et al.: Successful treatment with tenofavir in a Child C cirrhotic patient with lamivudine-resistant Hepatitis B virus awaiting liver transplantation. Post-transplant Results. Transplant International 2005, 18:879-883.